cell suspensions obtained from human breast tumors, 9 testicular seminomas, 11 and colorectal carcinomas 4 all overexpress Gb 3 . After its binding to the Gb 3 receptors, STxB uses the retrograde transport to deliver the A subunit to the cytosol: STxB enters cells through clathrin-independent or -dependent endocytosis, reaches the Golgi apparatus, and is then transported to the endoplasmic reticulum, from where the catalytic A subunit is retrotranslocated to the cytosol. 3, 12, 13 Here we show that the B-subunit of the Shiga toxin accumulates in two models of human colorectal carcinoma, after systemic in vivo administration. A fluorescence-tagged protein was administered to nude mice bearing xenografts overexpressing the Gb 3 receptor and its distribution was studied by optical imaging. Macroscopic observations were then correlated with confocal microscopy analysis to identify the targeted cells and to prove the entry of the protein in the Gb 3 -expressing cells.
Materials and Methods

Purification of STxB from Bacteria and Labeling
A variant of STxB carries a cysteine in its terminal chain, allowing conjugation of the protein with diverse molecules. 14 STxB was purified from bacteria as previously described, 15 dialyzed against phosphate-buffered saline (PBS), and coupled to fluorophores (Amersham Biosciences, Piscataway, NJ) according to the instructions from the supplier.
Cell Culture
HT29 human colon cancer cells were maintained at 37˚C in Dulbecco's Modified Eagle's Medium (with glutamine, high glucose, without pyruvate; Invitrogen, Cergy Pontoise, France), supplemented with 4 mM of glutamine (Gibco), 5 mM sodium pyruvate (Gibco), 10% fetal bovine serum (Gibco), and 1% of a penicillin-streptomycin-amphotericin mix (Invitrogen, Cergy Pontoise, France). HT29 cells were infected with the pTRIP-deltaU3-EF1alpha EGFP-lentiviral vector containing the eGFP gene (enhanced green fluorescent protein) under the control of the EF1 (elongation factor 1) promoter. 16 
Animals and Xenograft Models
Swiss nu/nu male or female mice were bred in the animal facilities of the Institut Curie, (Paris, France), or of the Commissariat à l'Energie Atomique, Service Hospitalier Frédéric Joliot (Orsay, France). The animals were maintained under specified pathogen-free conditions. Their care and housing were in accordance with the institutional guidelines of the French Ethical Committee (Ministère de l'Agriculture, Paris, France) and under the supervision of authorized investigators.
The TC302 tumor specimen was obtained with consent from a colon cancer patient during surgical resection of the tumor. The tumor sample was established as a xenograft by subcutaneous implantation of a tumor fragment into the scapular area of nude mice and sequentially transplanted. TC302 fragments of 30 to 60 mm 3 were grafted subcutaneously into the interscapular fat pad of 5-to 7-week-old Swiss nude mice, under tribromoethanol anesthesia.
HT29 xenografts were obtained by subcutaneously injecting 2.5 × 10 6 green fluorescent protein (GFP)expressing HT29 cells into nude mice, under isoflurane anesthesia.
Fluorescence Imaging
Biodistribution of fluorescent STxB in mice xenografted with GFP-expressing HT29 cells and TC302 tumor fragments was studied by fluorescence imaging. When the tumors reached approximately 250 mm 3 , the mice were injected with 50 µg of STxB-Cy5 (1.67 mg/kg). A PhotonImager optical camera (Biospace Lab) or an IVIS-Xenogen 100 system (Caliper Lifesciences) was used for optical imaging.
Acquisition parameters for the PhotonImager optical camera were as follows: excitation filter, 650 nm; emission filter, 715 nm; light intensity, 100%; aperture, 3.3; background correction filter, 520 nm. Fluorescent signal intensities were corrected for background and quantified using Photovision+ software (Biospace Lab).
Acquisition parameters for the IVIS-Xenogen 100 system (Caliper Lifesciences) were as follows: excitation filter, 615 to 665 nm; emission filter, 695 to 770 nm; background correction filter, 580 to 610 nm. The images were collected and processed using the Xenogen Living Image software (Caliper Lifesciences).
Immunohistochemical Analyses
Nude mice xenografted with GFP-expressing HT29 cells were injected intravenously with 100 µg of STxB-Cy5 (3.34 mg/kg). Tumors were collected 8 and 48 hours postinjection and incubated overnight at 4˚C in an aqueous solution containing 4% of paraformaldehyde, 10 mM PBS, 0.1 mM CaCl 2 , and 1.0 mM MgCl 2 . Tumors were then incubated for 24 hours at 4˚C in an aqueous solution containing 4% paraformaldehyde, 20% sucrose, 10 mM PBS, 0.1 mM CaCl 2 , and 1.0 mM MgCl 2 ; frozen in isopentane; and stored at -80˚C. Tumor sections (5.0 µm) were cut with a CM3050 cryostat (Leica). Tumor sections were stained with hematoxylin and eosin or incubated with monoclonal antibodies specific for CD34 (1 hour; 1:200 dilution; MEC 14.7: sc-18917; Santa Cruz Biotechnology) or CD11b (1 hour; 1:1,000 dilution; MCA711; Serptec). Secondary antibodies were goat antirabbit IgG coupled to Alexa594 (30 minutes; 1:1,000; A11007; Molecular Probes), and 4,6diamidino-2-phenylindole (DAPI) was used to stain nuclei. To label the Gb 3 sphingolipid, cryosections were incubated ex vivo for 30 minutes with STxB conjugated to the fluorophore Cy3, at a final concentration of 10 µg/mL in PBS containing 0.2% bovine serum albumin. Sections were observed under a confocal microscope (SP2, Leica; objective: ×63) equipped for epifluorescence.
Results
We used optical imaging to study the accumulation of fluorescently labeled STxB in TC302 xenografts after administration by various routes (Figure 1 ). After oral administration of STxB-Cy5 to TC302-xenografted nude mice, no STxB fluorescence was detected in the tumors. In contrast, after intraperitoneal injection of STxB-Cy5, fluorescence was observed in the xenograft from 5 hours to 5 days postinjection; the STxB was slowly eliminated by renal excretion. After intravenous injection, the STxB-Cy5 similarly reached xenografted tumors, but the fluorescent signal was higher and persisted longer (up to 7 days). We therefore chose the intravenous route for subsequent experiments.
The targeting of Gb 3 -positive tumors by STxB was also studied in nude mice xenografted with HT29 cells, a human colorectal carcinoma cell line overexpressing the Gb 3 . The HT29 cells were stably transfected with the GFP reporter gene before implantation into the mice. Fluorescent STxB was injected intravenously into the xenografted mice. Fluorescence was rapidly accumulated in the HT29 xenografts, and its elimination from the body was slow (Figure 2 ). Injection of fluorescent STxB in non-tumor-bearing mice showed that the biodistribution of the protein was the same as in the tumor-bearing mice (data not shown). STxB-Cy5 was eliminated mainly by the renal system. Fluorescence was also observed in the spleen, the liver, and, to a lesser extent, the intestine (Figure 3) . The tumor to muscle fluorescence ratio was 2.8 by 8 hours after the injection (Figure 2 ) and increased to 4.1 after 2 days, where it remained until day 4; thereafter, the ratio declined but was still 2.3 9 days postinjection.
Fluorescent STxB and GFP expression by cancerous cells allowed analysis of tumoral cell targeting at the cellular level by using confocal microscopy. Mice were sacrificed 8 and 48 hours after intravenous injection of STxB, and the tumors were collected. To compare the presence of fluorescent STxB and that of Gb 3 , tumor sections were stained ex vivo with STxB-Cy3 and observed by confocal microscopy (Figure 4 ). Despite a heterogeneous expression of Gb 3 on HT29 tumor cells, the staining revealed good colocalization of STxB-Cy5 and Gb 3 . STxB accumulated inside GFP-positive HT29 cells after both 8 and 48 hours ( Figure 5 ).
Moreover, accumulation of STxB was also observed in GFP-negative cells. To identify these targeted cells accurately, tumor sections were labeled with anti-CD11b antibody to detect infiltrating macrophages ( Figure 6 ) and with anti-CD34 antibody to reveal epithelial cells of new blood vessels (Figure 7) . The anti-CD11b antibody (also known as Mac-1, CR3, or Integrin αM, Itgam) binds to a transmembrane glycoprotein found on granulocytes, monocytes, natural killer cells, and subsets of T and B cells. This staining revealed the presence of an area of inflammation surrounding the xenografts and substantial accumulation of the STxB-Cy5 in CD11b-positive cells (see Figure 6 ); tumors collected 8 and 48 hours after STxB-Cy5 injection showed similar patterns. The anti-CD34 antibody is specific for a heavily glycosylated transmembrane glycoprotein expressed on hematopoietic progenitor and vascular endothelial cells. This staining showed that the epithelial cells of the new blood vessels also accumulated STxB (see Figure 7 , A-C). Most of the HT29 cells labeled with STxB-Cy5 were located near blood vessels (see Figure 7 , A-C). However, dual labeling for CD34 and Gb 3 showed that the strength of Gb 3 expression by HT29 cells was not correlated with the proximity to blood vessels (see Figure 7 , D-F), highlighting the role of the diffusion of STxB for explaining the heterogeneity of the protein accumulation.
Discussion
STxB has been used to study retrograde transport, and the mechanisms governing this pathway are now better known. 2, 17 STxB specifically enters Gb 3 -positive cells, and this sphingolipid is abundant on a large number of cancerous cells. Therefore, STxB is a potentially useful agent for drug vectoring, although there have been only a few detailed analyses of in vivo targeting of Gb 3 -overexpressing cells by STxB and its biodistribution after systemic administration. To assess the value of STxB as an in vivo vectorization agent, we used two models of colorectal carcinoma. Colorectal carcinomas-one of the most frequent tumors in Europe and North America-often overexpress Gb 3 . 5 The biodistribution of the STxB has been analyzed by positron emission tomography (PET) in a transgenic mouse model of spontaneous digestive tumorigenesis 4 : following per os or intravenous administration, STxB accumulated in intestinal tumor regions overexpressing Gb 3 . This PET study also showed that the radioactivity was eliminated through the urinary tract, as shown by high levels of radioactivity in the bladder and kidneys. Uptake was also observed in the spleen, lungs, and, to a lesser extent, the liver. In our xenograft models, STxB accumulation was also observed in Gb 3 -expressing tumor regions, confirming that cancerous cells are targeted in vivo after systemic injection. We also report that the STxB persisted for several days in the circulation and particularly in the xenografts. We observed that the main route of elimination of the protein was the urinary pathway, confirming the previous PET study. We also observed an accumulation of fluorescence in the liver and the intestine. In the PET study, no radioactivity could be detected in the abdominal region of wild-type mice, and only a slight labeling was observed in the liver. These differences may be due to the different methods of labeling or to the different species of mice. The presence of fluorescence in the kidneys, spleen, and liver confirms that it will be of primary importance to study the possible adverse effects on these organs during the development of new therapeutic strategies using STxB.
We also used fluorescently labeled STxB to compare macroscopic optical imaging patterns and the cellular distribution by confocal microscopy. Bartlett and colleagues showed that two compounds displaying similar tumor accumulation, as assessed by macroscopic analysis (by PET in their study), may have different intracellular and extracellular distributions in a tumor. 18 The use of a fluorescently labeled probe allows analysis of the tumor area at the cellular level to determine which types of cells are really targeted by the probe, if this targeting is receptor specific, and if the probe enters in the targeted cells. Confocal microscopy with tumor sections confirmed that STxB accumulated in HT29 cells expressing its receptor Gb 3 , demonstrating the efficacy of STxB as a vector for targeted delivery to Gb 3 -expressing tumor cells. STxB staining of the xenograft was heterogeneous, and there are two explanations: (1) accumulation of STxB in HT29 cells was enhanced by the proximity of blood vessels, and (2) Gb 3 expression by HT29 cells was not homogeneous throughout the xenograft. The epithelial cells of the new blood vessels also accumulated STxB. These in vivo findings are consistent with previous ex vivo observations of fluorescent Shiga toxin binding to the neovasculature of frozen tumor sections. 10, 19, 20 This specificity for neovasculature offers interesting possibilities for the STxB vector, including the delivery of antiangiogenic drugs, even to tumors that do not express Gb 3 . CD11b-positive cells (infiltrating macrophages, natural killer cells, and B-cell subpopulations) also accumulated STxB, offering opportunities for in vivo delivery of immunotherapeutic agents. Indeed, Vingert and colleagues demonstrated that Shiga toxin B subunit can target antigen to dendritic cells in vivo and can elicit antitumor immunity. 21 In conclusion, using two models of human colorectal carcinoma, we showed that STxB can target cells associated with Gb 3 -expressing tumors after a systemic injection. Furthermore, the protein entered Gb 3expressing cells, including the cancerous cells, as well as monocytes and macrophages and epithelial cells of the new blood vessels. These results illustrate the great potential of this protein as a vector for targeted antitumoral therapy.
